Vitamin D as a clinical biomarker in multiple sclerosis

Bibliography

• Handunnetthi L, Ramagopalan SV. UV radiation, vitamin D, and multiple sclerosis. Proc Natl Acad Sci USA 2010;107(33):E130; author reply E131
   PubMed Web of Science ®Google Scholar
• Orton SM, Wald L, Confavreux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011;76(5):425-31
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Handel AE, Giovannoni G, et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011;76(16):1410-14
   PubMed Web of Science ®Google Scholar
• Antico A, Tampoia M, Tozzoli R, et al. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012;12(2):127-36
   PubMed Web of Science ®Google Scholar
• Baarnhielm M, Hedstrom AK, Kockum I, et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol 2012;19(7):955-62
   PubMed Web of Science ®Google Scholar
• Disanto G, Chaplin G, Morahan JM, et al. Month of birth, vitamin D and risk of immune mediated disease: a case control study. BMC Med 2012;10(1):69
   PubMedGoogle Scholar
• Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets 2012;11(5):545-55
   PubMed Web of Science ®Google Scholar
• Munger KL, Chitnis T, Frazier AL, et al. Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol 2011;258(3):479-85
   PubMed Web of Science ®Google Scholar
• Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296(23):2832-8
   PubMed Web of Science ®Google Scholar
• Kampman MT, Steffensen LH, Mellgren SI, et al. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012;18(8):1144-51
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012;2012:452541
   PubMedGoogle Scholar
• Loken-Amsrud KI, Holmoy T, Bakke SJ, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology 2012;79(3):267-73
   PubMed Web of Science ®Google Scholar
• Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72(2):234-40
   PubMed Web of Science ®Google Scholar
• Runia TF, Hop WC, de Rijke YB, et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79(3):261-6
   PubMed Web of Science ®Google Scholar
• Stewart N, Simpson S Jr, van der Mei I, et al. Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79(3):254-60
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9(6):599-612
   PubMed Web of Science ®Google Scholar
• Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol 2012;25(3):246-51
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Kaneko I, et al. Molecular Mechanisms of Vitamin D Action. Calcif Tissue Int 2012;92(2):77-98
   PubMed Web of Science ®Google Scholar
• Handel AE, Disanto G, Jarvis L, et al. Seasonality of admissions with multiple sclerosis in Scotland. Eur J Neurol 2011;18(8):1109-11
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology 2011;76(21):1824-30
   PubMed Web of Science ®Google Scholar
• Handel AE, Gillie O, Ramagopalan SV. Inequities in advice on vitamin D? QJM 2011;104(6):547-9
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol 2009;23(6):789-95
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Dyment DA, Cader MZ, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70(6):881-6
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20(10):1352-60
   PubMed Web of Science ®Google Scholar
• Disanto G, Sandve GK, Berlanga-Taylor AJ, et al. Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Hum Mol Genet 2012;21(16):3575-86
   PubMed Web of Science ®Google Scholar
• Chao MJ, Barnardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A 2008;105(35):13069-74
   PubMed Web of Science ®Google Scholar
• Cocco E, Meloni A, Murru MR, et al. Vitamin D responsive elements within the HLA-DRB1 promoter region in Sardinian multiple sclerosis associated alleles. PLoS ONE 2012;7(7):e41678
   PubMedGoogle Scholar
• Nolan D, Castley A, Tschochner M, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology 2012;79(6):538-46
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93(15):7861-4
   PubMed Web of Science ®Google Scholar
• Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011;31(17):3653-69
   PubMed Web of Science ®Google Scholar
• Spach KM, Pedersen LB, Nashold FE, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics 2004;18(2):141-51
   PubMed Web of Science ®Google Scholar
• Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002;408(2):200-4
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6(11):1133-41
   PubMed Web of Science ®Google Scholar
• Spach KM, Nashold FE, Dittel BN, et al. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006;177(9):6030-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Marling SJ, Zhu JG, et al. Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor. Proc Natl Acad Sci U S A 2012;109(22):8501-4
   PubMed Web of Science ®Google Scholar
• Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58(2):227-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Kong J, Sun T, et al. 1,25-Dihydroxyvitamin D(3) suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-kappaB activation. Arch Biochem Biophys 2011;507(2):241-7
   PubMed Web of Science ®Google Scholar
• Giarratana N, Penna G, Amuchastegui S, et al. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004;173(4):2280-7
   PubMed Web of Science ®Google Scholar
• Moreno J, Krishnan AV, Peehl DM, et al. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006;26(4A):2525-30
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Miyake S, Mizuno M, et al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006;129(Pt 8):1984-92
   PubMedGoogle Scholar
• Muthian G, Raikwar HP, Johnson C, et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 2006;26(1):73-85
   PubMed Web of Science ®Google Scholar
• Carlson NG, Rojas MA, Redd JW, et al. Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. J Neuroinflammation 2010;7:25
   PubMedGoogle Scholar
• Carlson NG, Hill KE, Tsunoda I, et al. The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol 2006;174(1-2):21-31
   PubMed Web of Science ®Google Scholar
• Palumbo S, Toscano CD, Parente L, et al. The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination. J Neurochem 2012;121(3):418-27
   PubMed Web of Science ®Google Scholar
• Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009;9(5):575-81
   PubMed Web of Science ®Google Scholar
• Xie L, Li XK, Takahara S. Curcumin has bright prospects for the treatment of multiple sclerosis. Int Immunopharmacol 2011;11(3):323-30
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Wergeland S, Bakke S, et al. omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012;69(8):1044-51
   PubMed Web of Science ®Google Scholar
• Allen AC, Kelly S, Basdeo SA, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler 2012;18(12):1797-800
   PubMed Web of Science ®Google Scholar
• Effraimidis G, Badenhoop K, Tijssen JG, et al. Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. Eur J Endocrinol 2012;167(1):43-8
   PubMed Web of Science ®Google Scholar
• Munger KL, Levin LI, O'Reilly EJ, et al. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011;17(10):1185-93
   PubMed Web of Science ®Google Scholar
• Decard BF, von Ahsen N, Grunwald T, et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83(12):1170-3
   PubMed Web of Science ®Google Scholar
• Disanto G, Morahan JM, Barnett MH, et al. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78(11):823-32
   PubMed Web of Science ®Google Scholar
• Lossius A, Vartdal F, Holmoy T. Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2011;240-241:87-96
   PubMed Web of Science ®Google Scholar
• Disanto G, Meier U, Giovannoni G, et al. Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development? Expert Rev Neurother 2011;11(9):1221-4
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61(4):288-99
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9(7):727-39
   PubMed Web of Science ®Google Scholar
• Yenamandra SP, Hellman U, Kempkes B, et al. Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cell Mol Life Sci 2010;67(24):4249-56
   PubMed Web of Science ®Google Scholar
• Disanto G, Handel AE, Ramagopalan SV. Estrogen-vitamin D interaction in multiple sclerosis. Fertil Steril 2011;95(1):e3; author reply e4
   PubMed Web of Science ®Google Scholar
• Holmqvist P, Hammar M, Landtblom AM, et al. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril 2010;94(7):2835-7
   PubMed Web of Science ®Google Scholar
• Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci 2009;286(1-2):99-103
   PubMed Web of Science ®Google Scholar
• Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009;175:239-51
   PubMed Web of Science ®Google Scholar
• Barrera D, Avila E, Hernandez G, et al. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J Steroid Biochem Mol Biol 2007;103(3-5):529-32
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Swami S, Peng L, et al. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010;151(1):32-42
   PubMed Web of Science ®Google Scholar
• Yague JG, Garcia-Segura LM, Azcoitia I. Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells. Endocrine 2009;35(2):252-61
   PubMed Web of Science ®Google Scholar
• Cheema C, Grant BF, Marcus R. Effects of estrogen on circulating "free" and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest 1989;83(2):537-42
   PubMed Web of Science ®Google Scholar
• Nashold FE, Spach KM, Spanier JA, et al. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol 2009;183(6):3672-81
   PubMed Web of Science ®Google Scholar
• Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67(5):618-24
   PubMed Web of Science ®Google Scholar
• Pierrot-Deseilligny C, Rivaud-Pechoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord 2012;5(4):187-98
   PubMed Web of Science ®Google Scholar
• Mowry EM, Waubant E. Pediatric multiple sclerosis. Continuum (Minneap Minn) 2010;16(5 Multiple Sclerosis):181-92
   PubMedGoogle Scholar
• Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 2010;340:c1640
   PubMed Web of Science ®Google Scholar
• Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005;330(7483):120
   PubMed Web of Science ®Google Scholar
• Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33(1):159-71
   PubMed Web of Science ®Google Scholar
• Dorr J, Ohlraun S, Skarabis H, et al. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012;13:15
   PubMed Web of Science ®Google Scholar
• Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311(1-2):44-9
   PubMed Web of Science ®Google Scholar
• Grimaldi L, Barkhof FBeelke M, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2012;78(11):841
   PubMedGoogle Scholar
• Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77(17):1611-18
   PubMed Web of Science ®Google Scholar
• von Geldern G, Mowry EM. The influence of nutritional factors on the prognosis of multiple sclerosis. Nat Rev Neurol 2012;8(12):678-89
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Mehta BK, Ramanathan M, et al. Vitamin D and multiple sclerosis. Neurologist 2012;18(4):179-83
   PubMed Web of Science ®Google Scholar
• Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83(5):565-71
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30
   PubMed Web of Science ®Google Scholar
• Holmoy T, Kampman MT, Smolders J. Vitamin D in multiple sclerosis: implications for assessment and treatment. Expert Rev Neurother 2012;12(9):1101-12
   PubMed Web of Science ®Google Scholar
• Steffensen LH, Brustad M, Kampman MT. What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year? J Neurol 2013;26(1):182-8
   Google Scholar
• Saltyte Benth J, Myhr KM, Loken-Amsrud KI, et al. Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology 2012;39(2):84-93
   PubMed Web of Science ®Google Scholar
• Waschbisch A, Wenny I, Tallner A, et al. Physical activity in multiple sclerosis: a comparative study of vitamin D, brain-derived neurotrophic factor and regulatory T cell populations. Eur Neurol 2012;68(2):122-8
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Bol Y, Damoiseaux J, et al. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand 2011;124(3):171-5
   PubMed Web of Science ®Google Scholar
• Kirbas A, Kirbas S, Anlar O, et al. Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis. Acta Neurol Belg 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Moen SM, Celius EG, Sandvik L, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One 2012;7(9):e45703
   PubMed Web of Science ®Google Scholar
• Fernandes de Abreu DA, Ibrahim EC, Boucraut J, et al. Severity of experimental autoimmune encephalomyelitis is unexpectedly reduced in mice born to vitamin D-deficient mothers. J Steroid Biochem Mol Biol 2010;121(1-2):250-3
   PubMed Web of Science ®Google Scholar
• Fernandes de Abreu DA, Landel V, Barnett AG, et al. Prenatal vitamin d deficiency induces an early and more severe experimental autoimmune encephalomyelitis in the second generation. Int J Mol Sci 2012;13(9):10911-19
   PubMed Web of Science ®Google Scholar
• Disanto G, Handel AE, Morahan JM, et al. Comment on "Epigenetic reduction in invariant NKT cells following in utero vitamin D deficiency in mice". J Immunol 2011;186(7):3803-4
   PubMed Web of Science ®Google Scholar